(3S)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxaldehyde | 783349-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (3S)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxaldehyde
• 英文别名: (3S)-1,2,3,4-tetrahydroisoquinoline-3-carbaldehyde
• CAS: 783349-93-9
• 化学式: C₁₀H₁₁NO
• 分子量: 161.2
• InChiKey: VSVRNUOGWHXMDZ-JTQLQIEISA-N

物化性质

• 沸点：
  294.9±40.0 °C(Predicted)
• 密度：
  1.160±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME<br/>[FR] FORME CRISTALLINE D'UN HYDROCHLORURE DE QUINAPRIL ET PROCEDE DE PREPARATION DE CELLE-CI
  申请人：LUPIN LTD

  公开号：WO2004054980A1

  公开（公告）日：2004-07-01

  A novel crystalline form of quinapril hydrochloride of formula (I). An amorphous form of quinapril hydrochloride substantially free of impurities, specially diketopiperazine compound, and conforming to pharmacopoeial specifications formed from the said novel crystalline form of quinapril hydrochloride of formula (I). The crystalline quinapril hydrochloride is in the form nitroalkane solvate in which the nitroalkane is nitromethane, nitroethane and nitropropane. Each such nitroalkane solvate having particular characteristic X- ray diffraction patterns. A process for preparation of amorphous from of quinapril hydrochloride, substantially free of impurities, specially diketopiperazine compound, and conforming to pharmacopoeial specifications, using the novel crystalline quinapril hydrochloride as an intermediate. The process involves obtaining free base compound of formula (V) by adjusting the pH of a solution of the benzyl ester maleate salt of quinapril of formula (V) between 7.5-8.5 in a mixture of water and an organic solvent; catalytic hydrogenation of this compound (V) in an alcoholic solvent in the presence of concentrated hydrochloric acid or hydrogen chloride dissolved in an alcoholic solvent and in the presence of catalytic amounts of Pd/C to obtain a residue containing formula (I); crystallization of the said residue by evaporating the alcoholic solvent from a nitroalkane solvent to give crystalline quinapril hydrochloride, associated with a solvate of the nitroalkane solvent, and drying the crystalline quinapril hydrochloride nitroalkane solvate at a temperature between 40°C and 45°C under vacuum to give amorphous quinapril hydrochloride of formula (I).

  盐酸喹那普利的一种新颖结晶形式，其化学式为(I)。一种基本上无杂质的盐酸喹那普利无定形形式，特别是二酮哌嗪化合物，并且符合药典规格，由所述的盐酸喹那普利新颖结晶形式（化学式为I）形成。该结晶形式的盐酸喹那普利是以硝基烷为溶剂的溶剂化物，其中硝基烷是硝基甲烷、硝基乙烷和硝基丙烷。每一种这样的硝基烷溶剂化物都具有特定的特征X-射线衍射图谱。一种制备基本上无杂质，特别是二酮哌嗪化合物，并符合药典规格的盐酸喹那普利无定形形式的过程，使用新颖的结晶盐酸喹那普利作为中间体。该过程包括通过将喹那普利苯甲基酯马来酸盐（化学式为V）的水和有机溶剂混合溶液的pH值调整在7.5-8.5之间，获得自由碱化合物（化学式为V）；在醇溶剂中对该化合物（V）进行催化氢化，在浓盐酸或溶于醇溶剂中的氯化氢的存在下，以及在Pd/C的催化量存在下，获得含有化学式（I）的残留物；通过从硝基烷溶剂中蒸发醇溶剂使所述残留物结晶，得到与硝基烷溶剂的溶剂化物相关的结晶盐酸喹那普利，并在40°C至45°C的温度下，在真空下干燥结晶盐酸喹那普利硝基烷溶剂化物，得到无定形的盐酸喹那普利（化学式为I）。
• Peptidomimetic ligands for cellular receptors and ion channels
  申请人：Persons E. Paul

  公开号：US20070093522A1

  公开（公告）日：2007-04-26

  One aspect of the present invention relates to novel peptidomometic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands—agonists or antagonists—for various cellular receptors, e.g., G-protein-coupled receptors and opioid receptors, and various cellular ion channels, e.g., sodium and calcium. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels. In certain embodiments, compounds of the present invention preferentially or selectively agonize or antagonize μ opioid receptors. In certain embodiments, compounds of the present invention preferentially or selectively inhibit sodium or calcium ion channels and agonize or antagonize μ-opioid receptors.

  本发明的一个方面涉及新型肽类模拟化合物。本发明的第二个方面涉及将新型肽类模拟化合物用作各种细胞受体的配体-激动剂或拮抗剂，例如G蛋白偶联受体和阿片受体，以及各种细胞离子通道，例如钠和钙。在某些实施方式中，本发明的化合物优选或选择性地抑制钠或钙离子通道。在某些实施方式中，本发明的化合物优选或选择性地激动或拮抗μ阿片受体。在某些实施方式中，本发明的化合物优选或选择性地抑制钠或钙离子通道，并激动或拮抗μ阿片受体。
• LHRH analogs
  申请人：ABBOTT LABORATORIES

  公开号：EP0328090A2

  公开（公告）日：1989-08-16

  The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds has been alkylated.

  本发明涉及 LHRH 的新型 "伪 "非肽和十肽衍生物。更具体地说，本发明涉及至少有一个酰胺键的氮原子被烷基化的 LHRH 衍生物。
• Reduced size LHRH analogs
  申请人：ABBOTT LABORATORIES

  公开号：EP0328089A2

  公开（公告）日：1989-08-16

  The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.

  本发明涉及新型 LHRH 类似物。LHRH 类似物包括 LHRH 的 "伪 "六肽、七肽、八肽和非肽类似物，其中全部或部分氨基酸 1、2 和 3 已被去除，剩余的(2-9)、(2-10)、(3-9)、(3-10)、(4-9)或(4-10)肽与各种羧酸相连，取代了 LHRH 中的氨基酸 1、2 或 3。
• [EN] METHOD FOR PREPARING (S)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID BY MEANS OF CHEMOENZYMATIC METHOD<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ACIDE (S)-1,2,3,4-TÉTRAHYDROISOQUINOLÉINE-3-CARBOXYLIQUE AU MOYEN D'UN PROCÉDÉ CHIMIO-ENZYMATIQUE<br/>[ZH] 一种化学酶法制备(S)-1，2，3，4-四氢异喹啉-3-甲酸的方法
  申请人：TONGLI BIOMEDICAL CO LTD

  公开号：WO2020107780A1

  公开（公告）日：2020-06-04

  本发明公开了一种化学酶法制备(S)-1，2，3，4-四氢异喹啉-3-甲酸的方法，其包括：以外消旋1，2，3，4-四氢异喹啉-3-甲酸为底物，利用D-氨基酸氧化酶立体选择性催化R型异构体，经氧化脱氢生成相应的亚胺酸，S型异构体未被催化保留在反应体系中，亚胺酸经亚胺酸还原剂作用生成外消旋底物，再在D-氨基酸氧化酶的作用下被立体选择性催化其中的R型异构体，由此制备S型异构体。本发明方法反应收率可达80.6％以上，ee值＞99％，且具有反应条件温和、立体选择性强、反应效率高、产率高、工艺相对简单等特点。